Evaluation of the Antibody Persistence Beyond Five Years Aft... | Clinical Trial | StuddyBuddy@endsection Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07379151

Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

Conditions: Meningoccocal Disease

Sex: All
Ages: 7 Years – 36 Years
Healthy volunteers: Yes
Enrollment: 450
Sponsor: Serum Institute of India Pvt. Ltd.

Location: Centre pour le Développement des Vaccins du Mali, ex-Institut Marchoux, Ministry of Health, BP251 Bamako, Mali BP251 Bamako

Summary

This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.

Eligibility Criteria

Inclusion Criteria: * Written informed consent and assent (if applicable) Exclusion Criteria: * Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination * Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07379151). StuddyBuddy aggregates publicly available trial information.